Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.

BACKGROUND: Immunological mechanisms are increasingly recognized in the progression of myelodysplastic syndrome (MDS). Early-stage MDS (E-MDS) is characterized by autoimmune-mediated myelosuppression whereas late-stage MDS (L-MDS) involves immune evasion, giving dysplastic cells growth potential to...

Full description

Bibliographic Details
Main Authors: Lin-lin Shao, Lei Zhang, Yu Hou, Shuang Yu, Xin-guang Liu, Xiao-yang Huang, Yuan-xin Sun, Tian Tian, Na He, Dao-xin Ma, Jun Peng, Ming Hou
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3517399?pdf=render
id doaj-540f699098b04548988b30145e1f3632
record_format Article
spelling doaj-540f699098b04548988b30145e1f36322020-11-25T01:46:40ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-01712e5133910.1371/journal.pone.0051339Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.Lin-lin ShaoLei ZhangYu HouShuang YuXin-guang LiuXiao-yang HuangYuan-xin SunTian TianNa HeDao-xin MaJun PengMing HouBACKGROUND: Immunological mechanisms are increasingly recognized in the progression of myelodysplastic syndrome (MDS). Early-stage MDS (E-MDS) is characterized by autoimmune-mediated myelosuppression whereas late-stage MDS (L-MDS) involves immune evasion, giving dysplastic cells growth potential to progress into acute myeloid leukemia. T-helper (Th) 22 is involved in the pathogenesis of inflammatory autoimmunity and tumorigenesis. The roles of Th22 cells in the pathophysiology of E-MDS and L-MDS remain unsettled. DESIGN AND METHODS: We studied 37 MDS patients (E-MDS, n = 17; L-MDS, n = 20) and 20 healthy controls to characterize their peripheral blood (PB), as well as 25 MDS patients and 10 healthy controls to characterize their bone marrow(BM). The expression of Interleukin-22 (IL-22), IL-17 or interferon gamma (IFN-γ) was examined in E-MDS, L-MDS patients and controls by flow cytometry. The mRNA expression levels of RAR-related orphan receptor C (RORC), IL-6, tumor necrosis factor alpha (TNF-α) and IL-23 in peripheral blood mononuclear cells (PBMCs) were determined by real-time quantitative polymerase chain reaction. The levels of IL-22 and IL-17 both in PB and BM plasma were examined by enzyme-linked immunosorbent assay. RESULTS: In E-MDS, peripheral Th17 cells were significantly elevated and correlated with peripheral Th22 cells compared with healthy controls and L-MDS. Significantly higher levels of peripheral Th22 expansion, mRNA expression of IL-6, TNF-α and lower level of RORC mRNA expression were observed in L-MDS compared with E-MDS. No statistical difference was found in IL-23 mRNA expression or plasma IL-22, IL-17 levels among E-MDS, L-MDS and controls. CONCLUSIONS: Our data demonstrated that L-MDS cohort had increased frequencies of peripheral Th22 cells and higher mRNA expression levels of IL-6 and TNF-α, indicating that Th22 cells along with Th17 cells or not are involved in the dynamic immune responses of MDS.http://europepmc.org/articles/PMC3517399?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Lin-lin Shao
Lei Zhang
Yu Hou
Shuang Yu
Xin-guang Liu
Xiao-yang Huang
Yuan-xin Sun
Tian Tian
Na He
Dao-xin Ma
Jun Peng
Ming Hou
spellingShingle Lin-lin Shao
Lei Zhang
Yu Hou
Shuang Yu
Xin-guang Liu
Xiao-yang Huang
Yuan-xin Sun
Tian Tian
Na He
Dao-xin Ma
Jun Peng
Ming Hou
Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
PLoS ONE
author_facet Lin-lin Shao
Lei Zhang
Yu Hou
Shuang Yu
Xin-guang Liu
Xiao-yang Huang
Yuan-xin Sun
Tian Tian
Na He
Dao-xin Ma
Jun Peng
Ming Hou
author_sort Lin-lin Shao
title Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
title_short Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
title_full Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
title_fullStr Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
title_full_unstemmed Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
title_sort th22 cells as well as th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2012-01-01
description BACKGROUND: Immunological mechanisms are increasingly recognized in the progression of myelodysplastic syndrome (MDS). Early-stage MDS (E-MDS) is characterized by autoimmune-mediated myelosuppression whereas late-stage MDS (L-MDS) involves immune evasion, giving dysplastic cells growth potential to progress into acute myeloid leukemia. T-helper (Th) 22 is involved in the pathogenesis of inflammatory autoimmunity and tumorigenesis. The roles of Th22 cells in the pathophysiology of E-MDS and L-MDS remain unsettled. DESIGN AND METHODS: We studied 37 MDS patients (E-MDS, n = 17; L-MDS, n = 20) and 20 healthy controls to characterize their peripheral blood (PB), as well as 25 MDS patients and 10 healthy controls to characterize their bone marrow(BM). The expression of Interleukin-22 (IL-22), IL-17 or interferon gamma (IFN-γ) was examined in E-MDS, L-MDS patients and controls by flow cytometry. The mRNA expression levels of RAR-related orphan receptor C (RORC), IL-6, tumor necrosis factor alpha (TNF-α) and IL-23 in peripheral blood mononuclear cells (PBMCs) were determined by real-time quantitative polymerase chain reaction. The levels of IL-22 and IL-17 both in PB and BM plasma were examined by enzyme-linked immunosorbent assay. RESULTS: In E-MDS, peripheral Th17 cells were significantly elevated and correlated with peripheral Th22 cells compared with healthy controls and L-MDS. Significantly higher levels of peripheral Th22 expansion, mRNA expression of IL-6, TNF-α and lower level of RORC mRNA expression were observed in L-MDS compared with E-MDS. No statistical difference was found in IL-23 mRNA expression or plasma IL-22, IL-17 levels among E-MDS, L-MDS and controls. CONCLUSIONS: Our data demonstrated that L-MDS cohort had increased frequencies of peripheral Th22 cells and higher mRNA expression levels of IL-6 and TNF-α, indicating that Th22 cells along with Th17 cells or not are involved in the dynamic immune responses of MDS.
url http://europepmc.org/articles/PMC3517399?pdf=render
work_keys_str_mv AT linlinshao th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT leizhang th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT yuhou th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT shuangyu th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT xinguangliu th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT xiaoyanghuang th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT yuanxinsun th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT tiantian th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT nahe th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT daoxinma th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT junpeng th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
AT minghou th22cellsaswellasth17cellsexpanddifferentiallyinpatientswithearlystageandlatestagemyelodysplasticsyndrome
_version_ 1725017987352625152